Lichtenstein, Gary R.
Cohen, Benjamin L.
Salese, Leonardo
Modesto, Irene http://orcid.org/0000-0002-7144-6304
Wang, Wenjin
Chan, Gary
Ahmed, Haytham Mohamed
Su, Chinyu
Peyrin-Biroulet, Laurent
Clinical trials referenced in this document:
Documents that mention this clinical trial
PTU-001 Tofacitinib, an oral jak inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.123
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Next generation of small molecules in inflammatory bowel disease
https://doi.org/10.1136/gutjnl-2016-312912
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
https://doi.org/10.1007/s40271-022-00603-w
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
https://doi.org/10.1007/s10620-022-07794-0
Documents that mention this clinical trial
PTU-001 Tofacitinib, an oral jak inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.123
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Next generation of small molecules in inflammatory bowel disease
https://doi.org/10.1136/gutjnl-2016-312912
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
https://doi.org/10.1007/s40271-022-00603-w
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
https://doi.org/10.1007/s10620-022-07794-0
Funding for this research was provided by:
Pfizer
Article History
Received: 8 February 2022
Accepted: 5 December 2022
First Online: 4 February 2023
Declarations
:
: GRL has received research support and/or funding from Celgene, Janssen Ortho Biotech, Pfizer Inc, Takeda, and UCB; consultancy fees from AbbVie, American Regent, Celgene, Cellceutix, Eli Lilly, Endo Pharmaceuticals, Ferring Pharmaceuticals, Gilead Sciences, Janssen Ortho Biotech, Merck, Morphic Therapeutics, Pfizer Inc, Prometheus Laboratories Inc, Romark, Salix/Valeant, Shire, Takeda, and UCB; honoraria from the American College of Gastroenterology, American Regent, Gastroenterology and Hepatology, Merck, Romark, Springer Science and Business Media, and Up-To-Date; and royalties from Professional Communications Inc and SLACK Inc. BLC has been an advisory board member for AbbVie; has received consultancy or speaker fees from AbbVie; and received support/and or funding from Celgene, Bristol-Myers Squibb, Cornerstones, Pfizer Inc, Sublimity Therapeutics, Takeda, TARGET RWE, and Vindico. LS, IM, WW, GC, HMA, and CS are employees and stockholders of Pfizer Inc. LP-B has received honoraria from AbbVie, Allergan, Alma, Amgen, Arena, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Hikma, Index Pharmaceuticals, Janssen, MSD, Nestlé, Pfizer Inc, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Takeda, and Tillotts; grants from AbbVie, MSD, and Takeda; and is a stockholder of CTMA.
: All studies were conducted in compliance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice Guidelines. Study protocols were approved by the Institutional Review Board and/or Independent Ethics Committee at each of the investigational centers participating in the studies, or a central Institutional Review Board.
: Informed consent was obtained from all individual participants included in the study.